Jefferies Financial Group Boosts Alto Neuroscience (NYSE:ANRO) Price Target to $25.00

Alto Neuroscience (NYSE:ANRO) had its target price hoisted by analysts at Jefferies Financial Group from $15.00 to $25.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s target price points to a potential upside of 77.51% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the company. Robert W. Baird upped their target price on Alto Neuroscience from $10.00 to $16.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. Chardan Capital began coverage on Alto Neuroscience in a research note on Monday, September 29th. They issued a “buy” rating and a $15.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, October 8th. Finally, HC Wainwright upped their price target on shares of Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 24th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO traded up $0.68 during midday trading on Wednesday, reaching $14.08. 308,162 shares of the company traded hands, compared to its average volume of 642,884. The company has a market cap of $381.35 million, a price-to-earnings ratio of -5.91 and a beta of 2.90. The stock has a 50-day moving average price of $7.17 and a 200 day moving average price of $4.33. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $15.18. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Tuesday, November 11th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.18. Sell-side analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC increased its position in Alto Neuroscience by 1.5% in the 2nd quarter. Armistice Capital LLC now owns 1,624,000 shares of the company’s stock worth $3,573,000 after purchasing an additional 24,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in Alto Neuroscience by 1.9% in the third quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock worth $4,444,000 after buying an additional 20,702 shares during the last quarter. Marshall Wace LLP raised its position in Alto Neuroscience by 9.9% during the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after acquiring an additional 84,417 shares in the last quarter. AWM Investment Company Inc. lifted its stake in Alto Neuroscience by 31.1% in the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock valued at $1,948,000 after acquiring an additional 214,153 shares during the last quarter. Finally, Peapod Lane Capital LLC grew its position in Alto Neuroscience by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock worth $1,136,000 after acquiring an additional 3,106 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.